Abstract: Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE and deep vein thrombosis (DVT) are considered expressions of the same disease, termed as venous thromboembolism (VTE). In the present review, we describe and meta-analyze the efficacy and safety data available with the direct oral anticoagulants (DOAC; dabigatran, rivaroxaban, apixaban, edoxaban) in clinical trials testing these new compounds in the acute/ long-term and extended therapy of VTE, providing subgroup analyses in patients with index PE. We analyzed ten studies in 35,019 randomized patients. A total of 14,364 patients (41%) had index PE. In the acute/long-term treatment of VTE, the DOAC showed comparable efficacy in preventing recurrent VTE to standard treatment in patients with index PE (risk ratio [RR]: 0.88; 95% confidence interval [CI]: 0.70-1.11) and index DVT (RR: 0.93; 95% CI: 0.75-1.16) (P for subgroup differences =0.76). VTE recurrence depending on PE anatomical extension and presence/absence of right ventricular dysfunction was only reported in two trials, with results being consistent with those obtained in the overall study populations. In the single trial comparing extended therapy of VTE with DOAC versus warfarin, the point estimate for recurrent VTE tended to disfavor the DOAC in patients with index PE (RR: 2.05; 95% CI: 0.83-5.03) and in patients with index DVT (RR: 1.11; 95% CI: 0.49-2.50) (P for subgroup differences =0.32). In trials that compared DOAC versus placebo for extended therapy, the reduction in recurrent VTE was consistent in patients with PE (RR: 0.15; 95% CI: 0.01-1.82) and in patients with DVT (RR: 0.25; 95% CI: 0.10-0.61) (P for subgroup differences =0.71). The DOAC were associated with a consistently lower risk of clinically relevant bleeding (CRB) than standard treatment of acute VTE and higher risk of CRB than placebo for extended therapy of VTE regardless of index event. In summary, the DOAC were as effective as, and safer than, standard treatment of (hemodynamically stable) PE. Their efficacy in preventing recurrent VTE seemed consistent regardless of anatomical extension of PE (extensive, intermediate, or limit) or presence/absence of right ventricular dysfunction although the data are limited. For extended therapy, the DOAC were more effective than placebo in preventing recurrent VTE but were associated with an increase in CRB regardless of index event.
Introduction
Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE occurs when clots break off from deep vein walls (deep vein thrombosis [DVT] ), usually from the lower limbs, and travel through the right side of the heart to the pulmonary balance between the risk of VTE recurrences if anticoagulation is withdrawn and the risk of bleeding if it is continued. Patients with ongoing risk factors and patients with unprovoked VTE are often prescribed extended therapy, provided that the bleeding risk is not excessive. 7 Despite LMWH or fondaparinux being effective and safe, they still require daily parenteral subcutaneous administration. In addition, they are mainly cleared through the kidneys, and their use in patients with severe renal insufficiency may be problematic. On the other hand, the narrow therapeutic window and variability in response of VKA implies that frequent anticoagulant monitoring (using the prothrombin time and its reporting as the INR) is necessary to avoid a subtherapeutic anticoagulation associated with an increased risk of thrombosis or an excessive anticoagulation that increases the risk of bleeding. Such monitoring is inconvenient for patients and medical staff, and costly for health care payers.
In recent years, several direct oral anticoagulants (DOAC) have been developed for the treatment of VTE, among other indications. 8 DOAC directly inhibit either thrombin or activated factor X (FXa). 9 Among them, the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa ® , Boehringer Ingelheim, Ingelheim, Germany) 10 and the oral direct FXa inhibitors rivaroxaban (Xarelto ® , Bayer AG, Leverkusen, Germany ) 11 and apixaban (Eliquis ® , Bristol-Myers Squibb, New York, NY, USA) 12 are currently approved in the European Union, North America, and other regions in several indications related to anticoagulation, including the treatment of VTE, while the oral direct FXa inhibitor edoxaban (Lixiana ® , Daiichi-Sankyo, Tokyo, Japan) 13 is approved in Japan for thromboprophylaxis after major orthopedic surgery and is currently under regulatory review in the European Union and other regions for the treatment of VTE and for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Their pharmacology is well characterized (Table 1 ). [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] They are given orally in fixed doses once or twice daily, and they lack validated and available antidotes. [10] [11] [12] [13] In this review, we describe and meta-analyze the efficacy and safety data available with the DOAC in clinical trials testing these new compounds in VTE, with a focus on patients with index PE, and we discuss their potential advantages and drawbacks over existing therapies in patients with VTE. 
Methods

Bibliographic search
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Gómez-Outes et al terms: "dabigatran", "rivaroxaban", "apixaban", "edoxaban", and "pulmonary embolism". We also searched regulatory agencies' websites (European Medicines Agency, US Food and Drug Administration) and relevant conference proceedings related to anticoagulant therapy.
Study selection criteria
We included randomized controlled trials comparing a DOAC (dabigatran, rivaroxaban, apixaban, and edoxaban) with the standard treatment for acute VTE or with warfarin or placebo for extended treatment of VTE.
Data extraction and quality assessment
We collected outcome data on the overall trial populations as well as by index event at baseline: index PE (with or without concomitant DVT) or index DVT (without PE). Primary efficacy outcome was recurrent symptomatic VTE (ie, the composite of recurrent DVT, recurrent non-fatal PE, and VTE-related death) and primary safety outcome was clinically relevant bleeding (CRB) (ie, the composite of major and clinically relevant non-major bleeding). We also extracted data on clinical trials design (eg, superiority, non-inferiority, duration of treatment and follow-up, inclusion and exclusion criteria, and outcomes definitions), treatment characteristics (eg, dosage used in the experimental and control groups), and patients' characteristics (age and sex; percentage of patients evaluable for efficacy and safety). Study quality was assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomized studies. 31 
Data synthesis and analysis
We carried out direct comparisons between the DOAC and standard treatment (initial/long-term therapy), placebo or warfarin (extended therapy) on an intention-to-treat basis. 32 We included the randomized population in the overall analysis. Clinical outcomes were analyzed in subgroups of patients with index PE versus those with index DVT when disaggregated data were available. Subgroup analyses by index event (PE or DVT) were conducted in the assessable population for efficacy and safety, as reported in the original publications. A random effects meta-analysis was carried out by conventional methods, as described by DerSimonian and Laird. 33 Heterogeneity was assessed using the Cochran Q test 34 Table 2 ). Of them, 2,751 patients (35%) had index PE. Mean age of patients was 55-58 years across trials and 55%-61% were males ( Table 2 ). Ethnic group distribution was reported in seven trials. [36] [37] [38] [39] 42 Across studies, the majority of patients included were Caucasians (70%-95%), followed by Asians (2%-21%) and Blacks or African Americans (1%-4% Table 2 ).
Results
Characteristics of studies and patients
In the initial/long-term therapy of VTE, a single drug approach was used in rivaroxaban and apixaban trials, while heparin lead-in was used in dabigatran and edoxaban trials. Treatment durations ranged between 3 months and 12 months in clinical trials in the acute/long-term therapy of VTE and between 6 months and 18 months in the extended therapy of VTE ( Table 2 ). All studies in the acute/long-term therapy of VTE and Secondary Prevention of Venous Thrombo Embolism (VTE) (RE-MEDY) 42 study in extended therapy of VTE used a non-inferiority approach, while placebo-controlled studies in extended therapy of VTE were superiority trials ( 44 in studies with rivaroxaban, apixaban, and edoxaban, but all dabigatran studies used a different definition. 36 Time in therapeutic range (TTR) ranged between 57% and 65% across studies that included warfarin as control treatment (Table 2) . [36] [37] [38] [39] [40] [41] [42] Risk of bias was assessed as "low" in the eight doubleblinded studies and "uncertain" in the two open-label studies, EINSTEIN DVT and PE (Table 2 ).
Recurrent VTe initial and long-term treatment of VTe
In the overall populations, the DOAC were as effective as standard therapy (risk ratio were assessable for recurrent VTE (Figure 2A) . The DOAC showed comparable efficacy in preventing recurrent VTE to standard treatment in patients with index PE (RR: 0.88; 95% CI: 0.70-1.11) and index DVT (RR: 0.93; 95% CI: 0.75-1.16) (P for subgroup differences =0.76) (Figure 2A ).
VTE recurrence depending on PE anatomical extension and presence/absence of RVD was only reported in two trials. 39, 41 In EINSTEIN PE, the rates of recurrent VTE in the rivaroxaban versus standard-therapy group were 1.7% (10 of 597) versus 1.4% (8 of 576) among patients with anatomically extensive PE at baseline, respectively; 2.5% (35 of 1,392) versus 2.2% (31 of 1424) in intermediate PE, respectively; and 1.6% (5 of 309 patients) versus 1.3% (4 of 299) in limited PE at baseline, respectively. 39 In HOKUSAI-VTE, 28% (n=938) of patients with PE (n=3,319) had RVD (NT-pro-BNP level $500 pg/mL). The rate of recurrent VTE in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (HR: 0.52; 95% CI: 0.28-0.98). 41 Figure 2B and C) . In the single trial that compared a DOAC with warfarin for extended therapy of VTE (RE-MEDY), the point estimate for recurrent VTE tended to favor warfarin without significant differences between patients with index PE (RR: 2.05; 95% CI: 0.83-5.03) or index DVT (RR: 1.11; 95% CI: 0.49-2.50) (P for subgroup differences =0.32) ( Figure 2B ). In trials that compared the DOAC and placebo for extended therapy, the effect on recurrent VTE was also consistent in patients with PE (RR: 0.15; 95% CI: 0.01-1.82) and in patients with DVT (RR: 0.25; 95% CI: 0.10-0.61) (P for subgroup differences =0.71) ( Figure 2C ).
Clinically relevant bleeding initial and long-term treatment of VTe
The DOAC were associated with a lower risk of CRB than standard treatment in the overall population (RR: 0.72; 95% CI: 0.57-0.91), but there was evidence of statistical heterogeneity across studies (P,0.00001), mainly at the expense of a greater effect size in reduction of CRB in the studies with dabigatran and apixaban than in studies with rivaroxaban and edoxaban ( Figure 3) .
The risk of CRB versus standard treatment was consistent in patients with index PE (RR: 0.90; 95% CI: 0.80-1.02) and index DVT (RR: 0.87; 95% CI: 0.67-1.12) (P for subgroup differences =0.80) ( Figure 4A ).
extended therapy of VTe
The DOAC were associated with a lower risk of CRB than warfarin (RR: 0.55; 95% CI: 0.42-0.72) and a higher risk of CRB than placebo (RR: 2.61; 95% CI: 1.24-5.50). However, 
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DOAC in the treatment of venous thromboembolism there was evidence of statistical heterogeneity among placebocontrolled studies (P=0.02), mainly at expenses of a higher increase in bleeding in dabigatran and rivaroxaban studies than in the AMPLIFY-EXT study with apixaban ( Figure 3) . Disaggregated safety data of extended therapy in patients with PE or DVT were only available from AMPLIFY-EXT. 43 In that trial, the trend toward increase in risk of CRB with apixaban versus placebo was consistent in patients with index PE (RR: 1.82; 95% CI: 0.80-4.13) and index DVT (RR: 1.20; 95% CI: 0.66-2.18) (P for subgroup differences =0.42) ( Figure 4B ). No disaggregated data of CRB depending on index VTE were reported in the remaining three studies in the extended therapy. 38, 42 Clinical outcomes in anticoagulated patients with index Pe versus index DVT Recurrent VTE and mortality risk were similar in both clinical presentations (index PE and index DVT).
However, patients with index PE had more CRB complications than patients with index DVT during the initial/ long-term anticoagulation therapy (RR: 1.29; 95% CI: 1.18-1.42) ( Table 3) . Patients with index PE had similar clinical outcomes than patients with DVT during extended anticoagulation therapy (Table 3) .
Discussion
Overall, the DOAC seem associated with similar efficacy and lower bleeding risk than standard therapy following acute VTE. Our analysis shows that the efficacy and safety of the DOAC are consistent regardless of the clinical presentation of acute VTE as hemodynamically stable PE or DVT. The analysis is based on six clinical trials in the initial/long-term therapy of VTE (range: 3-12 months of treatment). [36] [37] [38] [39] [40] [41] These studies included a total of 11,589 randomized patients with index PE and 15,434 randomized patients with index DVT. Across trials, 24%-46% of patients with index PE had 
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DOAC in the treatment of venous thromboembolism anatomically extensive PE, [39] [40] [41] and 28% of patients with index PE had RVD. 41 Available data in these subgroups, although scarce, suggest that the effect in patients with index PE is consistent regardless of anatomical extension of PE, 34 or presence/absence of RVD. 41 In the extended therapy, we found a reduction in recurrent VTE with the DOAC in comparison with placebo, which was also consistent in patients with PE and in patients with DVT. On the contrary, the point estimate for the RR of recurrent VTE disfavored dabigatran versus warfarin in the RE-MEDY trial, particularly in patients with PE. Moreover, the trend toward a poorer efficacy of dabigatran versus warfarin during extended therapy of VTE was further suggested by the numerical increase in acute coronary syndromes (ACS) (13 versus three patients). The TTR in RE-MEDY was 65%, better than in all the remaining studies with the DOAC in the treatment of VTE. These data may suggest that patients with index PE who remain well controlled while on extended therapy with warfarin should not generally be switched to dabigatran, as it could potentially result in an increased risk of thromboembolism. Since the RE-MEDY trial is so far the only study comparing the DOAC and warfarin in extended anticoagulant therapy in patients with VTE, these results must be interpreted with caution and are not necessarily applicable with other DOAC. Moreover, in the RE-SONATE study (extended therapy with dabigatran or placebo), the rates of recurrent VTE and ACS with dabigatran (0.4% and 0.1%, respectively) were much lower than those in the dabigatran arm of the RE-MEDY study (1.8% and 0.9%, respectively). These differences could be explained by an optimal quality of anticoagulation with warfarin in RE-MEDY and by different baseline risk of treatment groups and follow-up duration between trials. Whether dabigatran increases the risk of ACS or the findings are due to a more protective effect of warfarin than of dabigatran against ACS is still unclear.
In extended therapy, dabigatran showed a significantly lower risk of bleeding than warfarin in RE-MEDY, 42 which is consistent with the lower bleeding tendency of all DOAC versus standard initial/long-term therapy. On the contrary, we found an increase in CRB with the DOAC versus placebo, which was heterogeneous across trials. The heterogeneity found may be due to differences in bleeding definitions across trials or might reflect differences in the bleeding profile of each of the DOAC, as they are different compounds with unique pharmacological characteristics. Head-to-head comparisons between the DOAC are needed to solve this issue.
Important differences are apparent between trials regarding the dosing regime (single-drug approach used in rivaroxaban and apixaban trials versus heparin lead-in used in dabigatran and edoxaban trials) that have implications when prescribing the DOAC in patients with VTE (Table 4 ). In addition, there are other issues to bear in mind when prescribing the new compounds, like their potential for drugdrug of food-drug interactions and appropriate use in renal insufficiency (Table 4) .
A single-drug regimen with rivaroxaban or apixaban may simplify treatment of acute PE, thus allowing for outpatient treatment in low-risk PE 6 or early discharge in intermediaterisk PE patients and potentially reducing hospital stays. A post hoc analysis of EINSTEIN studies has shown that the proportion of hospitalized patients for PE with a length of stay of 5 days or fewer receiving rivaroxaban was 45% compared with 33% for enoxaparin/VKA. 45 Reduction in subsequent hospitalizations after initial discharge has been reported with apixaban in the acute/long-term therapy versus standard treatment (AMPLIFY) 46 and during extended therapy versus placebo (AMPLIFY-EXT). 47 Limitations of these analyses include their post hoc nature and well-monitored clinical trial setting, in which decisions on admission and discharge could vary from real-world management.
The DOAC may provide an alternative to warfarin for extended therapy of PE, particularly in those patients considered to be at high risk of bleeding. Patients with VTE and cancer are among those patients who have a high risk of both recurrence and bleeding. DOAC have shown promising results in patients with cancer in comparison with warfarin. 48, 49 However, LMWH instead of VKA is the standard of care in VTE associated with cancer. 50 Further head-to-head comparative trials between the DOAC and LMWH are needed to recommend the use of the DOAC in VTE associated with cancer.
Heparin-induced thrombocytopenia (HIT) is a rare but serious complication of heparin treatment. 51 DOAC may provide an alternative for anticoagulation in patients with VTE and with history of HIT, because they do not interact with PF4 in vitro. [52] [53] [54] A clinical study is underway to investigate rivaroxaban for treatment of patients with current suspected or confirmed HIT (n=200) (Clinicaltrials.gov identifier: NCT01598168). 55 The lack of validated and currently available antidotes is one of the drawbacks of the DOAC. 48 Adequate supportive care and temporary removal of all antithrombotic drugs constitute the basis for management of serious bleeding complications. 56 
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Gómez-Outes et al activated prothrombin complex concentrate and activated factor VIIa) have been tried for the DOAC with varying success. 56 Hemodialysis can remove 50%-60% of circulating dabigatran, 10 while administration of activated charcoal may be useful to reduce absorption of rivaroxaban or apixaban if taken ,6 hours after overdose or accidental ingestion. 11, 12 Highly specific reversal agents for the direct thrombin and FXa inhibitors are under development and might be available during the next years. 56 Other drawbacks of the DOAC include their higher costs in comparison with VKA and the uncertainty about the adherence to therapy in day-to-day practice. Since the DOAC have a shorter half-life (,24 hours) than warfarin (36-42 hours), suboptimal adherence may be more dangerous for the DOAC than for warfarin. Furthermore, some DOAC have twice-daily dosing schedules (Table 4) , which may be more difficult for some patients with DVT or PE to adhere to than a daily regimen, particularly in the long term. 57 However, no head-to-head comparisons for checking compliance with once-daily versus twice-daily regimes of DOAC are available, and therefore no firm conclusions can be drawn in this respect.
Conclusion
The DOAC are as effective as, and probably safer than standard treatment of hemodynamically stable PE. The efficacy and safety of the DOAC seem consistent regardless anatomical extension of PE (extensive, intermediate, or limit) or presence/absence of RVD, although the data are limited. For extended therapy, the DOAC are more effective than placebo in preventing recurrent VTE but are associated with an increase in CRB either in patients with PE or DVT.
